* intubation and mechanical ventilation in the course of covid19 or reception of convalescent covid19 plasma treatment at any time prior to study entry * major psychiatric conditions including but not restricted to (e.g. attention deficit/hyperactivity disorder, substance use disorder, schizophrenia documented in patient history or diagnosed using m.i.n.i), at the discretion of the site investigator, these do not refer to patients with typical mild to moderate symptoms of depression and anxiety associated with pasc * neurological signs and symptoms including change in level of consciousness, seizures, movement disorders or focal neurological deficits, disorders of the central nervous system with tissue damage or a pre-covid-19 diagnosis of chronic fatigue syndrome documented in the patient history or diagnosed during the neurological examination * current immunosuppressive//immunomodulating medication (e.g., azathioprine, tacrolimus, cyclosporine, methotrexate, hydroxychloroquine, cytotoxic chemotherapy, or neutralizing antibodies against sars-cov-2 epitopes) or therapy with hiv protease inhibitors

* intubation and mechanical ventilation in the course of covid19 or reception of convalescent covid19 plasma treatment at any time prior to study entry * major psychiatric conditions including but not restricted to (e.g. attention deficit/hyperactivity disorder, substance use disorder, schizophrenia documented in patient history or diagnosed using m.i.n.i), at the discretion of the site investigator, these do not refer to patients with typical mild to moderate symptoms of depression and anxiety associated with pasc * neurological signs and symptoms including change in level of consciousness, seizures, movement disorders or focal neurological deficits, disorders of the central nervous system with tissue damage or a pre-covid-19 diagnosis of chronic fatigue syndrome documented in the patient history or diagnosed during the neurological examination * current immunosuppressive//immunomodulating medication (e.g., azathioprine, tacrolimus, cyclosporine, methotrexate, hydroxychloroquine, cytotoxic chemotherapy, or neutralizing antibodies against sars-cov-2 epitopes) or therapy with hiv protease inhibitors

intubation and mechanical ventilation in the course of covid19 or reception of convalescent covid19 plasma treatment at any time prior to study entry major psychiatric conditions including but not restricted to (e.g. attention deficit/hyperactivity disorder, substance use disorder, schizophrenia documented in patient history or diagnosed using m.i.n.i), at the discretion of the site investigator, these do not refer to patients with typical mild to moderate symptoms of depression and anxiety associated with pasc neurological signs and symptoms including change in level of consciousness, seizures, movement disorders or focal neurological deficits, disorders of the central nervous system with tissue damage or a pre-covid-19 diagnosis of chronic fatigue syndrome documented in the patient history or diagnosed during the neurological examination current immunosuppressive//immunomodulating medication (e.g., azathioprine, tacrolimus, cyclosporine, methotrexate, hydroxychloroquine, cytotoxic chemotherapy, or neutralizing antibodies against sars-cov-2 epitopes) or therapy with hiv protease inhibitors

intubation and mechanical ventilation in the course of covid19 or reception of convalescent covid19 plasma treatment at any time prior to study entry major psychiatric conditions including but not restricted to (e.g. attention deficit/hyperactivity disorder, substance use disorder, schizophrenia documented in patient history or diagnosed using m.i.n.i), at the discretion of the site investigator, these do not refer to patients with typical mild to moderate symptoms of depression and anxiety associated with pasc neurological signs and symptoms including change in level of consciousness, seizures, movement disorders or focal neurological deficits, disorders of the central nervous system with tissue damage or a pre-covid-19 diagnosis of chronic fatigue syndrome documented in the patient history or diagnosed during the neurological examination current immunosuppressive//immunomodulating medication (e.g., azathioprine, tacrolimus, cyclosporine, methotrexate, hydroxychloroquine, cytotoxic chemotherapy, or neutralizing antibodies against sars-cov-2 epitopes) or therapy with hiv protease inhibitors

intubation and mechanical ventilation in the course of covid19 or reception of convalescent covid19 plasma treatment at any time prior to study entry major psychiatric conditions including but not restricted to (attention deficit/hyperactivity disorder, substance use disorder, schizophrenia documented in patient history or diagnosed using m.i.n.i), at the discretion of the site investigator, these do not refer to patients with typical mild to moderate symptoms of depression and anxiety associated with pasc neurological signs and symptoms including change in level of consciousness, seizures, movement disorders or focal neurological deficits, disorders of the central nervous system with tissue damage or a pre-covid-19 diagnosis of chronic fatigue syndrome documented in the patient history or diagnosed during the neurological examination current immunosuppressive//immunomodulating medication (e.g., azathioprine, tacrolimus, cyclosporine, methotrexate, hydroxychloroquine, cytotoxic chemotherapy, or neutralizing antibodies against sars-cov-2 epitopes) or therapy with hiv protease inhibitors

intubation and mechanical ventilation in the course of covid19 or reception of convalescent covid19 plasma treatment at any time prior to study entry major psychiatric conditions including but not restricted to (attention deficit/hyperactivity disorder, substance use disorder, schizophrenia documented in patient history or diagnosed using m.i.n.i), at the discretion of the site investigator, these do not refer to patients with typical mild to moderate symptoms of depression and anxiety associated with pasc neurological signs and symptoms including change in level of consciousness, seizures, movement disorders or focal neurological deficits, disorders of the central nervous system with tissue damage or a pre-covid-19 diagnosis of chronic fatigue syndrome documented in the patient history or diagnosed during the neurological examination current immunosuppressive//immunomodulating medication (e.g., azathioprine, tacrolimus, cyclosporine, methotrexate, hydroxychloroquine, cytotoxic chemotherapy, or neutralizing antibodies against sars-cov-2 epitopes) or therapy with hiv protease inhibitors

intubation and mechanical ventilation in the course of covid19 or reception of convalescent covid19 plasma treatment at any time prior to study entry major psychiatric conditions including but not restricted to (attention deficit/hyperactivity disorder, substance use disorder, schizophrenia documented in patient history or diagnosed using m.i.n.i), at the discretion of the site investigator, these do not refer to patients with typical mild to moderate symptoms of depression and anxiety associated with pasc neurological signs and symptoms including change in level of consciousness, seizures, movement disorders or focal neurological deficits, disorders of the central nervous system with tissue damage or a pre-covid-19 diagnosis of chronic fatigue syndrome documented in the patient history or diagnosed during the neurological examination current immunosuppressive medication (e.g., azathioprine, tacrolimus, cyclosporine, methotrexate, hydroxychloroquine, cytotoxic chemotherapy, or neutralizing antibodies against sars-cov-2 epitopes) or therapy with hiv protease inhibitors

intubation and mechanical ventilation in the course of covid19 or reception of convalescent covid19 plasma treatment at any time prior to study entry major psychiatric conditions including but not restricted to (attention deficit/hyperactivity disorder, substance use disorder, schizophrenia documented in patient history or diagnosed using m.i.n.i), at the discretion of the site investigator, these do not refer to patients with typical mild to moderate symptoms of depression and anxiety associated with pasc neurological signs and symptoms including change in level of consciousness, seizures, movement disorders or focal neurological deficits, disorders of the central nervous system with tissue damage or a pre-covid-19 diagnosis of chronic fatigue syndrome documented in the patient history or diagnosed during the neurological examination current immunosuppressive medication (e.g., azathioprine, tacrolimus, cyclosporine, methotrexate, hydroxychloroquine, cytotoxic chemotherapy, or neutralizing antibodies against sars-cov-2 epitopes) or therapy with hiv protease inhibitors

intubation and mechanical ventilation in the course of covid19 or reception of convalescent covid19 plasma treatment at any time prior to study entry major psychiatric conditions including but not restricted to (attention deficit/hyperactivity disorder, substance use disorder, schizophrenia documented in patient history or diagnosed using m.i.n.i) these do not refer to patients with typical mild to moderate symptoms of depression and anxiety associated with pasc neurological signs and symptoms including change in level of consciousness, seizures, movement disorders or focal neurological deficits, disorders of the central nervous system with tissue damage or a pre-covid-19 diagnosis of chronic fatigue syndrome documented in the patient history or diagnosed during the neurological examination current immunosuppressive medication (e.g., azathioprine, tacrolimus, cyclosporine, methotrexate, hydroxychloroquine, cytotoxic chemotherapy, or neutralizing antibodies against sars-cov-2 epitopes) or therapy with hiv protease inhibitors

intubation and mechanical ventilation in the course of covid19 or reception of convalescent covid19 plasma treatment at any time prior to study entry major psychiatric conditions including but not restricted to (attention deficit/hyperactivity disorder, substance use disorder, schizophrenia documented in patient history or diagnosed using m.i.n.i) these do not refer to patients with typical mild to moderate symptoms of depression and anxiety associated with pasc neurological signs and symptoms including change in level of consciousness, seizures, movement disorders or focal neurological deficits, disorders of the central nervous system with tissue damage or a pre-covid-19 diagnosis of chronic fatigue syndrome documented in the patient history or diagnosed during the neurological examination current immunosuppressive medication (e.g., azathioprine, tacrolimus, cyclosporine, methotrexate, hydroxychloroquine, cytotoxic chemotherapy, or neutralizing antibodies against sars-cov-2 epitopes) or therapy with hiv protease inhibitors